|
1
|
DeBerardinis RJ, Lum JJ, Hatzivassiliou G
and Thompson CB: The biology of cancer: Metabolic reprogramming
fuels cell growth and proliferation. Cell Metab. 7:11–20. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vander Heiden MG: Targeting cancer
metabolism: A therapeutic window opens. Nat Rev Drug Discov.
10:671–684. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Farwell MD, Pryma DA and Mankoff DA:
PET/CT imaging in cancer: Current applications and future
directions. Cancer. 120:3433–3445. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuntz S, Mazerbourg S, Boisbrun M, Cerella
C, Diederich M, Grillier-Vuissoz I and Flament S: Energy
restriction mimetic agents to target cancer cells: Comparison
between 2-deoxyglucose and thiazolidinediones. Biochem Pharmacol.
92:102–111. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim EH, Lee JH, Oh Y, Koh I, Shim JK, Park
J, Choi J, Yun M, Jeon JY, Huh YM, et al: Inhibition of
glioblastoma tumorspheres by combined treatment with 2-deoxyglucose
and metformin. Neuro Oncol. 19:197–207. 2017.PubMed/NCBI
|
|
6
|
Pusapati RV, Daemen A, Wilson C, Sandoval
W, Gao M, Haley B, Baudy AR, Hatzivassiliou G, Evangelista M and
Settleman J: mTORC1-dependent metabolic reprogramming underlies
escape from glycolysis addiction in cancer cells. Cancer Cell.
29:548–562. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Swerdlow RH, E L, Aires D and Lu J:
Glycolysis-respiration relationships in a neuroblastoma cell line.
Biochim Biophys Acta. 1830:2891–2898. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wei S, Kulp SK and Chen CS: Energy
restriction as an antitumor target of thiazolidinediones. J Biol
Chem. 285:9780–9791. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mazerbourg S, Kuntz S, Grillier-Vuissoz I,
Berthe A, Geoffroy M, Flament S, Bordessa A and Boisbrun M:
Reprofiling of troglitazone towards more active and less toxic
derivatives: A new hope for cancer treatment? Curr Top Med Chem.
16:2115–2124. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moon SH, Lee SJ, Jung KH, Quach CH, Park
JW, Lee JH, Cho YS and Lee KH: Troglitazone stimulates cancer cell
uptake of 18F-FDG by suppressing mitochondrial respiration and
augments sensitivity to glucose restriction. J Nucl Med.
57:129–135. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shannon CE, Daniele G, Galindo C,
Abdul-Ghani MA, DeFronzo RA and Norton L: Pioglitazone inhibits
mitochondrial pyruvate metabolism and glucose production in
hepatocytes. FEBS J. 284:451–465. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vacanti NM, Divakaruni AS, Green CR,
Parker SJ, Henry RR, Ciaraldi TP, Murphy AN and Metallo CM:
Regulation of substrate utilization by the mitochondrial pyruvate
carrier. Mol Cell. 56:425–435. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Reitzer LJ, Wice BM and Kennell D:
Evidence that glutamine, not sugar, is the major energy source for
cultured HeLa cells. J Biol Chem. 254:2669–2676. 1979.PubMed/NCBI
|
|
14
|
Yuneva M, Zamboni N, Oefner P,
Sachidanandam R and Lazebnik Y: Deficiency in glutamine but not
glucose induces MYC-dependent apoptosis in human cells. J Cell
Biol. 178:93–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Takeuchi Y, Nakayama Y, Fukusaki E and
Irino Y: Glutamate production from ammonia via glutamate
dehydrogenase 2 activity supports cancer cell proliferation under
glutamine depletion. Biochem Biophys Res Commun. 495:761–767. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vichai V and Kirtikara K: Sulforhodamine B
colorimetric assay for cytotoxicity screening. Nat Protoc.
1:1112–1116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rampelt H and van der Laan M: Metabolic
remodeling: A pyruvate transport affair. EMBO J. 34:835–837. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Corbet C, Bastien E, Draoui N, Doix B,
Mignion L, Jordan BF, Marchand A, Vanherck JC, Chaltin P, Schakman
O, et al: Interruption of lactate uptake by inhibiting
mitochondrial pyruvate transport unravels direct antitumor and
radiosensitizing effects. Nat Commun. 9:12082018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang C, Ko B, Hensley CT, Jiang L, Wasti
AT, Kim J, Sudderth J, Calvaruso MA, Lumata L, Mitsche M, et al:
Glutamine oxidation maintains the TCA cycle and cell survival
during impaired mitochondrial pyruvate transport. Mol Cell.
56:414–424. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gibbons JJ, Abraham RT and Yu K: Mammalian
target of rapamycin: Discovery of rapamycin reveals a signaling
pathway important for normal and cancer cell growth. Semin Oncol.
36 (Suppl 3):S3–S17. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hidalgo M and Rowinsky EK: The
rapamycin-sensitive signal transduction pathway as a target for
cancer therapy. Oncogene. 19:6680–6686. 2000. View Article : Google Scholar : PubMed/NCBI
|
